An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade

Hongchuan Liu, Rui Wang, Duopeng An, Hui Liu, Fan Ye, Baoxian Li, Jing Zhang, Peixiang Liu, Xuyao Zhang, Sheng Yao, Ziyang Zhong, Hui Feng, Meiqing Feng